October 13, 2021 | Highland, MD – The Jayne Koskinas Ted Giovanis Foundation for Health and Policy has extended prior JKTGF funded research to Heiko Enderling, Ph.D., a faculty member of Moffitt Cancer Center, to support his work personalizing radiation therapy to better fight breast cancer.

It is now widely recognized that breast cancer therapy should be tailored to individual patients. While patient-specific data has affected the decision for use of chemotherapy, it has yet to impact radiation therapy, the single most used therapeutic treatment in oncology.

This research seeks to decipher the architecture of the tumor-immune ecosystem in biopsy tissues to identify the optimal radiation protocol – on a per-patient basis – to induce robust immunity and eradicate the tumor.

“Radiation therapy is the most used therapy for fighting breast cancer, yet no clinical trials have attempted to individualize it,” said Ted Giovanis, founder and president of the JKTG Foundation.

“Heiko’s research has challenged current practice with exciting results, and the Foundation is pleased to further support his work so future breast cancer patients benefit from individualized treatment and better outcomes.”

Featured news

JKTG Funding @ Work

JKTG Funding @ Work

The research, Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin, includes work by Andrew Ewald, PhD, with Johns Hopkins University School of Medicine, a researcher with whom JKTG has worked on several projects.

read more

Jayne Koskinas Ted Giovanis
Foundation for Health and Policy

PO Box 130
Highland, Maryland 20777

Media contact: 202.548.0133